Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies

Table 1 Laboratory and clinical parameters of the patients before IVIG therapy

Patient	Disease (ILAR Patient criteria)	Disease duration*	Joint erosion	Treatment	IgG antibodies		IgM antibodies		B19 DNA^†		Anti-PL IgG
					VP1/VP2	NS1	VP1/VP2	NS1	Serum	SF	Anti-CL	Anti-PS	Anti-β₂GPI
1	RF-positive polyarthritis	23	+	NSAID	++	-	++	-	10³	10²	-	-	++
				MTX
				TCHA
				Prednisolone (iv/oral)
2	Psoriatic arthritis	96	+	NSAID	++	+	+	-	4 × 10³	3 × 10²	-	-	+
				MTX
				TCHA
3	Psoriatic arthritis	48	-	NSAID	++	+	-	-	2 × 10³	6 × 10³	-	-	-
				MTX
				TCHA
				Prednisone
4	Reactive arthritis	125	-	NSAID	++	-	-	-	6 × 10²	10³	-	-	++
				Choroquine
				Prednisone
				Sulphasalazine

*Months before IVIG therapy. ^†Genome equivalents per ml of sample. Anti-β₂GPI, anti-β₂-glycoprotein I; anti-CL, anti-cardiolipin; anti-PL IgG; antiphospholipid antibodies; anti-PS, anti-phosphatidylserine; ILAR, International League of Associations for Rheumatology; iv, intravenous; IVIG, high-dose intravenous immunoglobulin; MTX, methotrexate; NS1, nonstructural protein 1; NSAID, nonsteroidal anti-inflammatory drugs; RF, rheumatoid factor; SF, synovial fluid; TCHA, intra-articularly injected crystalline glucosteroids; VP1, viral protein 1; VP2, viral protein 2.

ISSN: 1478-6362